190 related articles for article (PubMed ID: 35007498)
1. Impact of Concomitant Medication Burden on Tolerability of Disease-targeted Therapy and Survival in Interstitial Lung Disease.
Khor YH; Goh NSL; Wong AW; Johannson KA; Marcoux V; Fisher JH; Assayag D; Manganas H; Khalil N; Kolb M; Ryerson CJ;
Ann Am Thorac Soc; 2022 Jun; 19(6):962-970. PubMed ID: 35007498
[No Abstract] [Full Text] [Related]
2. Therapeutic burden in interstitial lung disease: Lessons to learn.
Khor YH; Glaspole I; Goh NSL
Respirology; 2019 Jun; 24(6):566-571. PubMed ID: 30790404
[TBL] [Abstract][Full Text] [Related]
3. Treatment Initiation in Patients with Interstitial Lung Disease in Canada.
Assayag D; Garlick K; Johannson KA; Fell CD; Kolb M; Cox G; Hambly N; Manganas H; Morisset J; Fisher JH; Shapera S; Gershon AS; To T; Sadatsafavi M; Wilcox PG; Halayko AJ; Khalil N; Ryerson CJ
Ann Am Thorac Soc; 2021 Oct; 18(10):1661-1668. PubMed ID: 33493425
[No Abstract] [Full Text] [Related]
4. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
Feng H; Zhao Y; Li Z; Kang J
Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
[TBL] [Abstract][Full Text] [Related]
5. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
Lamb YN
Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
[TBL] [Abstract][Full Text] [Related]
6. Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease.
Gibson CD; Kugler MC; Deshwal H; Munger JS; Condos R
Lung; 2020 Aug; 198(4):597-608. PubMed ID: 32591895
[TBL] [Abstract][Full Text] [Related]
7. The impact of antifibrotic use on long-term clinical outcomes in the pulmonary fibrosis foundation registry.
Lee CT; Hao W; Burg CA; Best J; Kolenic GE; Strek ME
Respir Res; 2024 Jun; 25(1):255. PubMed ID: 38907239
[TBL] [Abstract][Full Text] [Related]
8. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
Torrisi SE; Kahn N; Wälscher J; Sarmand N; Polke M; Lars K; Eichinger M; Heussel CP; Palmucci S; Sambataro FM; Sambataro G; Sambataro D; Vancheri C; Kreuter M
BMC Pulm Med; 2019 Nov; 19(1):213. PubMed ID: 31718637
[TBL] [Abstract][Full Text] [Related]
9. South-West of England's Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF).
Barratt SL; Mulholland S; Al Jbour K; Steer H; Gutsche M; Foley N; Srivastava R; Sharp C; Adamali HI
Front Pharmacol; 2018; 9():1480. PubMed ID: 30618768
[No Abstract] [Full Text] [Related]
10. Real life data on nintedanib safety: idiopathic pulmonary fibrosis versus systemic sclerosis-interstitial lung disease and strategies adopted to manage adverse effects.
Di Battista M; Tavanti L; Pistelli F; Carrozzi L; Da Rio M; Rossi A; Puccetti L; Tavoni A; Romei C; Morganti R; Della Rossa A; Mosca M
Inflammopharmacology; 2023 Oct; 31(5):2445-2449. PubMed ID: 37535212
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and tolerability of antifibrotics in rheumatoid arthritis-associated interstitial lung disease.
Juge PA; Hayashi K; McDermott GC; Vanni KMM; Kowalski E; Qian G; Bade K; Saavedra A; Dieudé P; Dellaripa PF; Doyle TJ; Sparks JA
Semin Arthritis Rheum; 2024 Feb; 64():152312. PubMed ID: 38056314
[TBL] [Abstract][Full Text] [Related]
12. Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients.
Bondue B; Castiaux A; Van Simaeys G; Mathey C; Sherer F; Egrise D; Lacroix S; Huaux F; Doumont G; Goldman S
Respir Res; 2019 Jan; 20(1):10. PubMed ID: 30646908
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of patients with advanced idiopathic pulmonary fibrosis treated with nintedanib or pirfenidone in a real-world multicentre cohort.
Durheim MT; Bendstrup E; Carlson L; Sutinen EM; Hyldgaard C; Kalafatis D; Myllärniemi M; Sköld CM; Sjåheim T
Respirology; 2021 Oct; 26(10):982-988. PubMed ID: 34291523
[TBL] [Abstract][Full Text] [Related]
14. A cohort study of Danish patients with interstitial lung diseases: burden, severity, treatment and survival.
Hyldgaard C
Dan Med J; 2015 Apr; 62(4):B5069. PubMed ID: 25872544
[TBL] [Abstract][Full Text] [Related]
15. Incidence and Prognostic Significance of Hypoxemia in Fibrotic Interstitial Lung Disease: An International Cohort Study.
Khor YH; Gutman L; Abu Hussein N; Johannson KA; Glaspole IN; Guler SA; Funke-Chambour M; Geiser T; Goh NSL; Ryerson CJ
Chest; 2021 Sep; 160(3):994-1005. PubMed ID: 33905679
[TBL] [Abstract][Full Text] [Related]
16. Use of nintedanib in interstitial lung disease other than idiopathic pulmonary fibrosis: much caution is warranted.
Mura M
Pulm Pharmacol Ther; 2021 Feb; 66():101987. PubMed ID: 33387612
[TBL] [Abstract][Full Text] [Related]
17. [Antifibrotic therapy - new approvals for non-IPF interstitial lung diseases].
Markart P; Drakopanagiotakis F; Wygrecka M
Dtsch Med Wochenschr; 2021 Feb; 146(3):181-184. PubMed ID: 33513653
[TBL] [Abstract][Full Text] [Related]
18. Family History of Pulmonary Fibrosis Predicts Worse Survival in Patients With Interstitial Lung Disease.
Cutting CC; Bowman WS; Dao N; Pugashetti JV; Garcia CK; Oldham JM; Newton CA
Chest; 2021 May; 159(5):1913-1921. PubMed ID: 33484728
[TBL] [Abstract][Full Text] [Related]
19. Review series: Aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ?
de Lauretis A; Veeraraghavan S; Renzoni E
Chron Respir Dis; 2011; 8(1):53-82. PubMed ID: 21339375
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Approach to Adult Fibrotic Lung Diseases.
Adegunsoye A; Strek ME
Chest; 2016 Dec; 150(6):1371-1386. PubMed ID: 27521738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
